Williams-Macdonald Sarah E, Mitchell Mairi, Frew David, Palarea-Albaladejo Javier, Ewing David, Golde William T, Longbottom David, Nisbet Alasdair J, Livingstone Morag, Hamilton Clare M, Fitzgerald Stephen F, Buus Søren, Bach Emil, Dinkla Annemieke, Roest Hendrik-Jan, Koets Ad P, McNeilly Tom N
Moredun Research Institute, Pentlands Science Park, Bush Loan, Penicuik, Midlothian EH26 0PZ, UK.
Biomathematics and Statistics Scotland, JCMB, The King's Buildings, Peter Guthrie Tait Road, Edinburgh EH9 3FD, UK.
Vaccines (Basel). 2023 Feb 22;11(3):511. doi: 10.3390/vaccines11030511.
The bacterium can cause the disease Q-fever in a wide range of animal hosts. Ruminants, including sheep, are thought to play a pivotal role in the transmission of to humans; however, the only existing livestock vaccine, namely, Coxevac (Ceva Animal Health Ltd., Libourne, France), a killed bacterin vaccine based on phase I strain Nine-Mile, is only approved for use in goats and cattle. In this study, a pregnant ewe challenge model was used to determine the protective effects of Coxevac and an experimental bacterin vaccine based on phase II against challenge. Prior to mating, ewes ( = 20 per group) were vaccinated subcutaneously with either Coxevac, the phase II vaccine, or were unvaccinated. A subset of pregnant ewes ( = 6) from each group was then challenged 151 days later (~100 days of gestation) with 10 infectious mouse doses of , Nine-Mile strain RSA493. Both vaccines provided protection against challenge as measured by reductions in bacterial shedding in faeces, milk and vaginal mucus, and reduced abnormal pregnancies, compared to unvaccinated controls. This work highlights that the phase I vaccine Coxevac can protect ewes against infection. Furthermore, the phase II vaccine provided comparable levels of protection and may offer a safer and cost-effective alternative to the currently licensed vaccine.
这种细菌可在多种动物宿主中引发Q热。反刍动物，包括绵羊，被认为在向人类传播[病原体名称未明确给出]方面起着关键作用；然而，现有的唯一一种家畜疫苗，即Coxevac（法国利布尔讷的塞瓦动物健康有限公司），一种基于I相菌株Nine-Mile的灭活菌苗疫苗，仅被批准用于山羊和牛。在本研究中，使用怀孕母羊攻毒模型来确定Coxevac和一种基于II相[病原体名称未明确给出]的实验性菌苗疫苗对[病原体名称未明确给出]攻毒的保护效果。在配种前，母羊（每组20只）皮下接种Coxevac、II相疫苗或不接种疫苗。然后，每组的一部分怀孕母羊（每组6只）在151天后（约妊娠100天）用10个感染性小鼠剂量的[病原体名称未明确给出]，Nine-Mile菌株RSA493进行攻毒。与未接种疫苗的对照组相比，两种疫苗通过减少粪便、乳汁和阴道黏液中的细菌排出量以及减少异常妊娠，提供了针对[病原体名称未明确给出]攻毒的保护。这项工作突出表明I相疫苗Coxevac可以保护母羊免受[病原体名称未明确给出]感染。此外，II相疫苗提供了相当水平的保护，并且可能为目前已获许可的疫苗提供一种更安全且具成本效益的替代方案。
